Hormonal adjuvants for the treatment of renal anaemia

European Journal of Clinical Investigation, Supplement

Volumn 35, Issue 3, 2005, Pages 75-84

  Deicher, R ^a   Horl W H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Androgens; Chronic kidney disease; IGF 1; Parathyroid hormone; Vitamin D; Zinc

Indexed keywords

ANDROGEN; COLECALCIFEROL; ERYTHROPOIETIN; GROWTH HORMONE; NANDROLONE DECANOATE; PARATHYROID HORMONE; SOMATOMEDIN C; VITAMIN D; ZINC;

ADJUVANT THERAPY; ANEMIA; BIOAVAILABILITY; BONE MARROW CELL; CALCIUM HOMEOSTASIS; COLLAGEN SYNTHESIS; COLONY FORMING UNIT; COLONY FORMING UNIT E; DIET SUPPLEMENTATION; DRUG EFFECT; ERYTHROPOIESIS; HEMODIALYSIS; HORMONAL THERAPY; HUMAN; HYPERPARATHYROIDISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; KIDNEY DISEASE; LIVER TOXICITY; PHYSICAL PERFORMANCE; POLYCYTHEMIA; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; STROMA CELL; VEIN THROMBOSIS; VIRILIZATION; WEIGHT GAIN;

EID: 28944438194     PISSN: 0960135X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2005.01533.x     Document Type: Review

References (105)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis 2001;37 (Suppl. 1):S182-238.
2. Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993;328:171-5.
3. Zingraff J, Drüeke T, Marie P, Man NK, Jungers P, Bordier P. Anemia and secondary hyperparathyroidism. Arch Intern Med 1978;138:1650-2.
4. Barbour GL. Effect of parathyroidectomy on anemia in chronic renal failure. Arch Intern Med 1979;139:889-91.
5. Drüeke TB, Eckardt KU. Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol Dial Transplant 2002;17 (Suppl. 5):28-31.
6. Mandolfo S, Malberti F, Farina M, Villa G, Scanziani R, Sudan M et al. Parathyroidectomy and response to erythropoietin therapy in anaemic patients with chronic renal failure [letter]. Nephrol Dial Transplant 1998;13:2708-9.
7. Meytes D, Bogin E, Ma A, Dukes PP, Massry SG. Effect of parathyroid hormone on erythropoiesis. J Clin Invest 1981;67:1263-9.
8. McGonigle RJS, Wallin JD, Husserl F, Deftos LJ, Rice JC, O'Neill WJ et al. Potential role of parathyroid hormone as an inhibitor of erythropoiesis in the anemia of renal failure. J Lab Clin Med 1984;104:1016-26.
9. Komatsuda A, Hirokawa M, Haseyama T, Horiuchi T, Wakui H, Imai H et al. Human parathyroid hormone does not influence human erythropoiesis in vitro. Nephrol Dial Transplant 1998;13:2088-91.
10. Bogin E, Massry SG, Levi J, Djaldeti M, Bristol G, Smith J. Effect of parathyroid hormone on osmotic fragility of human erythrocytes. J Clin Invest 1982;69:1017-25.
11. Wu SG, Jeng FR, Wei SY, Su CZ, Chung TC, Chang WJ et al. Red blood cell osmotic fragility in chronically hemodialyzed patients. Nephron 1998;78:28-32.
12. Urena P, Eckardt KU, Sarfati E, Zingraff J, Zins B, Roullet JB et al. Serum erythropoietin and erythropoiesis in primary and secondary hyperparathyroidism: effect of parathyroidectomy. Nephron 1991;59:384-93.
13. Rapoport J, Mostoslavski M, Ben-David A, Knecht A, Blau A, Arad J et al. Successful treatment of secondary hyperparathyroidism in hemodialysis patients with oral pulse 1-alpha-hydroxy-cholecalciferol therapy. Nephron 1996;72:150-4.
14. Goicoechea M, Vazquez MI, Ruiz MA, Gomez-Campdera F, Perez-Garcia R, Valderrabano F. Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients. Nephron 1998;78:23-7.
15. Washio M, Iseki K, Onoyama K, Oh Y, Nakamoto M, Fujimi S et al. Elevation of serum erythropoietin after subtotal parathyroidectomy in chronic haemodialysis patients. Nephrol Dial Transplant 1992;7:121-4.
16. Yasunaga C, Matsuo K, Yanagida T, Matsuo S, Nakamoto M, Goya T. Early effects of parathyroidectomy on erythropoietin production in secondary hyperparathyroidism. Am J Surg 2002;183:199-204.
17. Di Iorio BR, Minutolo R, De Nicola L, Bellizzi V, Catapano F, Iodice C et al. Supplemented very low protein diet ameliorates responsiveness to erythropoietin in chronic renal failure. Kidney Int 2003;64:1822-8.
18. Klausen T, Ghisler U, Mohr T, Fogh-Andersen N. Erythropoietin, 2,3 diphosphoglycerate and plasma volume during moderate altitude training. Scand J Med Sci Sports 1992;2:16-20.
19. Klausen T, Poulsen TD, Fogh-Andersen N, Richalet JP, Nielsen OJ, Olsen NV. Diurnal variations of serum erythropoietin at sea level and altitude. Eur J Appl Physiol Occup Physiol 1996;72:297-302.
20. Argiles A, Lorho R, Mourad G, Mion CM. High-dose alfacalcidol for anaemia in dialysis [letter]. Lancet 1993;342:378-9.
21. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Schohn D, Chuet C. High-dose alfacalcidol improves anaemia in patients on haemodialyis. Nephrol Dial Transplant 1997;12:514-8.
22. 3 treatment [letter]. Clin Nephrol 2002;57:487-8.
23. 3 and retinoic acid on normal human pluripotent (CPU-mix), erythroid (BFU-E), and myeloid (CFU-C) progenitor cell growth and differentiation patterns. Exp Hematol 1986;14:60-5.
24. Orsatti MB, Puche RC. Adverse effect of 1,25-dihydroxycholecalciferol on erythrocyte precursors in the rat. Acta Physiol Pharmacol Latinoam 1986;36:397-402.
25. 3 in the myelodysplastic syndromes. Blood 1986;67:1154-61.
26. 3 metabolites on normal and leukemic bone marrow cells in vitro. Int J Cell Cloning 1984;2:227-42.
27. 3 regulate in vitro and in vivo the response to human recombinant erythropoietin in CAPD patients. Adv Perit Dial 1990;6:312-15.
28. 3 on signal transduction systems in colonic cells. Steroids 1999;64:137-42.
29. Aucella F, Gatta G, Vigilante M, Scalzulli RP, Mantuano S, Carotenuto M et al. Calcitriol increases burst forming unit-erythroid (BFU-E) in vitro proliferation in chronic uremia. Synergic effect with DNA recombinant erythropoietin (rHu-Epo). Minerva Urol Nefrol 2001;53:1-5.
30. 3. Cancer Lett 1995;90:225-30.
31. 3 in induction of erythroid progenitor cell proliferation. Exp Hematol 2002;30:403-9.
32. Blazsek I, Misset JL, Comisso M, Mathe G. Hematon: a multicellular functional unit in primary hematopoiesis. Biomed Pharmacother 1988;42:661-70.
33. 3 deficiency underlying human myeloid leukemias. Cancer Detect Prev 1996;20:3l-42.
34. 3, in control of the hematopoietic cell cycle. Biomed Pharmacother 1991;45:157-68.
35. Kurella M, Butterly DW, Smith SR. Post transplant erythrocytosis in hypercalcemic renal transplant recipients. Am J Transplant 2003;3:873-7.
36. Veldhuis JD, Wilkowski MJ, Zwart AD, Urban RJ, Lizarralde G, Iranmanesh A et al. Evidence for attenuation of hypothalamic gonadotropin-releasing hormone (GnRH) impulse strength with preservation of GnRH pulse frequency in men with chronic renal failure. J Clin Endocrinol Metab 1993;76:648-54.
37. Veldhuis JD, Johnson ML, Wilkowski MJ, Iranmanesh A, Bolton WK. Neuroendocrine alterations in the somatotrophic axis in chronic renal failure. Acta Paediatr Scand Suppl 1991;379:12-22.
38. Orskov H, Hausensen AP, Hansen HE, Alberti KG, Noy GA, Nosadini R. Acetate: inhibitor of growth hormone hypersecretion in diabetic and non-diabetic uraemic subjects. Acta Endocrinol (Copenh) 1982;99:551-8.
39. Christ ER, Cummings MH, Westwood NB, Sawyer BM, Pearson TC, Sönksen PH et al. The importance of growth hormone in the regulation of erythropoiesis, red cell mass, and plasma volume in adults with growth hormone deficiency. J Clin Endocrinol Metabol 1997;82:2985-90.
40. Sohmiya M, Kato Y. Effect of long-term administration of recombinant human growth hormone (rhGH) on plasma erythropoietin (EPO) and hemoglobin levels in anaemic patients with adult GH deficiency. Clin Endocrinol 2001;55:749-54.
41. Iglesias P, Diez JJ, Fernandex-Reyes MJF, Aguilera A, Burgues S, Martinez-Ara J et al. Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized trial. Am J Kidney Dis 1998;32:454-63.
42. Johannsson G, Bengtsson BA, Ahlmen J. Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement. Am J Kidney Dis 1999;33:709-17.
43. Sohmiya M, Ishikawa K, Kato Y. Stimulation of erythropoietin secretion by continuous subcutaneous infusion of recombinant human GH in anemic patients with chronic renal failure. Eur J Endocrinol 1998;138:302-6.
44. Deicher R, Hörl WH. Anemia as a risk factor for the progression of chronic kidney disease. Curr Opin Nephrol Hypertens 2003;12:139-43.
45. Fisher J. Erythropoietin: physiology and pharmacology update. Exp Biol Med 2003;228:1-14.
46. Powell DR, Rosenfeld RG, Baker BK, Liu F, Hintz RL. Serum somatomedin levels in adults with chronic renal failure: the importance of measuring insulin-like growth factor-I (IGF-I) and IGF-II in acid-chromatographed uremic serum. J Clin Endocrinol Metab 1986;63:1186-92.
47. Goldberg AC, Trivedi B, Delmez JA, Harter HR, Daughaday WH. Uremia reduces serum insulin-like growth factor I, increases insulin like growth factor II, and modifies their serum protein binding. J Clin Endocrinol Metab 1982;55:1040-5.
48. Shih LY, Huang JY, Lee CT. Insulin-like growth factor I plays a role in regulating erythropoiesis in patients with end-stage renal disease and erythrocytosis. J Am Soc Nephrol 1999;10:315-22.
49. Urena P, Bonnardeaux A, Eckardt KU, Kurtz A, Drüeke TB. Insulin-like growth factor I: a modulator of erythropoiesis in uremic patients? Nephrol Dial Transplant 1992;7:40-4.
50. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocrinol Rev 1997;18:801-31.
51. Phillips LS, Fusco AC, Unterman TG, del Greco F. Somatomedin inhibitor in uremia. J Clin Endocrinol Metab 1984;59:764-74.
52. Powell D, Rosenfeld R, Sperry J, Baker B, Hintz R. Serum concentration of insulin-like growth factor (IGF)-I, IGF-II and unsaturated somatomedin carrier proteins in children with chronic renal failure. Am J Kidney Dis 1987;10:287-92.
53. Brox AG, Zhang F, Guyda H, Gagnon RF. Subtherapeutic erythropoietin and insulin-like growth factor-1 correct the anemia of chronic renal failure in the mouse. Kidney Int 1996;50:937-45.
54. Miyagawa SH, Kobayashi M, Konishi N, Sato T, Ueda K. Insulin and insulin-like growth factor I support the proliferation of erythroid progenitor cells in bone marrow through the sharing of receptors. Br J Haematol 2000;109:555-62.
55. Levin A. The relationship of haemoglobin level and survival: direct or indirect effects? Nephrol Dial Transplant 2002;17 (Suppl. 5):8-13.
56. Underwood LE. Nutritional regulation of IGF-1 and IGFBPs. J Pediatr Endocr Metab 1996;9:303-12.
57. Suliman ME, Qureshi AR, Barany P, Stenvinkel P, Filho JC, Anderstam B et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000;57:1727-35.
58. Prasad A, Miale A, Farid Z, Schubert A, Sandstead H. Zinc metabolism in patients with the syndrome of iron deficiencies, anemia, hypogonadism, and dwarfism. J Lab Clin Med 1963;61:537-45.
59. King LE, Fraker PJ. Zinc deficiency in mice alters myelopoiesis and hematopoiesis. J Nutr 2002;132:3301-7.
60. Mahajan SK, Bowersox EM, Rye DL, Abu-Hamdan DK, Prasad AS, McDonald FD et al. Factors underlying abnormal zinc metabolism in uremia. Kidney Int Suppl 1989;27:S269-73.
61. Shapera MR, Moel DI, Kamath SK, Olson R, Beauchamp GK. Taste perception of children with chronic renal failure. J Am Diet Assoc 1986;86:1359-62.
62. Wallaeys B, Cornelis R, Mees L, Lameire N. Trace elements in serum, packed cells, and dialysate of CAPD patients. Kidney Int 1986;30:599-604.
63. Danielson BG, Fellstrom B, Nilsson P, Weiss L, Wikstrom B. Trace element levels in patients with renal failure and after transplantation. Acta Pharmacol Toxicol 1986;59:438-41.
64. Lee SH, Huang JW, Hung KY, Leu LJ, Kan YT, Yang CS et al. Trace metals' abnormalities in hemodialysis patients: realationship with medications. Artif Organs 2000;24:841-4.
65. Caticha O, Norato DY, Tambascia Ma Santana A, Stephanou A, Sarlis NJ. Total body zinc depletion and its relationship to the development of hyperprolactinemia in chronic renal insufficiency. J Endocrinol Invest 1996;19:441-8.
66. Briggs WA, Pedersen MM, Mahajan SK, Sillix DH, Prasad AS, McDonald FD. Lymphocyte and granulocyte function in zinc-treated and zinc-deficient hemodialysis patients. Kidney Int 1982;21:827-32.
67. Bolze MS, Reeves RD, Lendbeck FE, Elders MJ. Influence of zinc on growth, somatomedin, and glycosaminoglycan metabolism in rats. Am J Physiol 1987;252:E21-6.
68. Cossack ZT. Somatomedin-C in zinc deficiency. Experimentia 1984;40:498-500.
69. Dorup I, Flyvbjerg A, Everts ME, Clausen T. Role of insulin-like growth factor-1 and growth hormone in growth inhibition induced by magnesium and zinc deficiencies. Br J Nutr 1991;66:505-21.
70. Roth HP, Kirchgessner M. Influence of alimentary zinc deficiency on the concentration of growth hormone, insulin-like growth factor-1 (IGF-1) and insulin in the serum of force-fed rats. Horm Metab Res 1994;26:404-8.
71. Cossak ZT. Somatomedin-C and zinc status in rats as affected by Zn, protein and food intake. Br J Nutr 1986;56:163-9.
72. McNall AK, Etherton TD, Fosmire GJ. The impaired growth induced by zinc deficiency in rats is associated with decreased expression of the hepatic insulin-like growth factor 1 and growth hormone receptor genes. J Nutr 1995;125:874-9.
73. Ninh NX, Thissen JP, Maiter D, Adam E, Mulimba N, Ketelslegers JM. Reduced liver insulin-like growth factor-I gene expression in young zinc-deprived rats is associated with a decrease in liver growth hormone (GH) receptors and serum GH-binding protein. J Endocrinol 1995;144:449-56.
74. O'Dell BL, Emery M. Compromised zinc status in rats adversely affects calcium metabolism in platelets. J Nutr 1991;121:1763-8.
75. Browning JD, O'Dell BL. Low zinc status in guinea pigs impairs calcium uptake by brain synaptosomes. J Nutr 1994;124:436-43.
76. Cossack ZT. Decline in somatomedin-C, insulin-like growth factor-1, with experimentally induced zinc deficiency in human subjects. Clin Nutr (Edinb) 1991;10:284-91.
77. Nakamura T, Nishiyama S, Suginohara YF, Matsuda I, Higashi A. Mild to moderate zinc deficiency in short children. Effect of zinc supplementation on linear growth velocity. J Pediatr 1993;123:65-9.
78. Payne-Robinson HM, Golden BE, Simeon OT, The zinc sandwich and growth. Lancet 1991;337:925-6.
79. Nishiyama S, Kiwaki K, Miyazaki Y, Hasuda T. Zinc and IGF-1 concentrations in pregnant women with anemia before and after supplementation with iron and/or zinc. J Am Coll Nutr 1999;18:261-7.
80. Pequignot JM, Spielvogel H, Caceres E, Rodriguez A, Sempore B, Pequignot J et al. Influence of gender and endogenous sex steroids on catecholaminergic structures involved in physiological adaptation to hypoxia. Pflugers Arch 1997;433:580-6.
81. Fonseca R, Rajkumar SV, White WL, Tefferi A, Hoagland HC. Anemia after orchiectomy. Am J Hematol 1998;59:230-3.
82. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997;79:933-41.
83. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxiciry. Urology 2003;61 (2 Suppl. 1):32-8.
84. Ellegala DB, Alden TD, Couture DE, Vance ML, Maartens NF, Laws ER Jr. Anemia, testosterone, and pituitary adenoma in men. J Neurosurg 2003;98:974-7.
85. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000;85:2670-7.
86. Gorsheim D, Murphy S, Gardner F. Comparative study on the erythropoietic effects of androgens and their mode of action. J Appl Physiol 1973;35:376-8.
87. Neff M, Goldberg J, Slifkin R, Eiser AR, Calamia V, Kaplan M et al. A comparison of androgens for anemia in patients on hemodialysis. N Engl J Med 1981;304:871-5.
88. Teruel JL, Aguilera A, Marcen R, Antolin JN, Otero GG, Ortuno J. Androgen therapy for anaemia of chronic renal failure. Scand J Urol Nephrol 1996;30:403-8.
89. Teruel J, Marcen R, Navarro J, Villafruela JJ, Fernandez Lucas M, Liano F et al. Evolution of serum erythropoietin after androgen administration to hemodialysis patients. A prospective study. Nephron 1995;70:282-6.
90. Fried W, Gurney CW. The erythropoietic-stimulating effects of testosterone. Ann NY Acad Sci 1968;149:356-65.
91. Hait WN, Gorshein D, Jepson JH, Besa EC, Gardner FH. 19-Nortestosterone decanoate induced erythropoiesis in the actinomycin-D-treated hyperoxic mouse. Biochem Biophys Res Commun 1972;47:426-31.
92. Gorshein D, Hait WN, Besa EC, Jepson JH, Gardner FH. Rapid stem cell differentiation induced by 19-nortestosterone decanoate. Br J Haematol 1974;26:215-25.
93. Parker PA, Izard MW, Maher JF. Therapy of iron deficiency in patients on maintenance dialysis. Nephron 1979;23:181-6.
94. Reeves WB, Fairman RM, Haurani FI. Influence of hormones on the release of iron by macrophages. J Reticuloendothel Soc 1981;29:173-9.
95. Solomon LR, Hendler ED. Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematol 1988;79:12-19.
96. Navarro JF, Mora C, Macia M, Garcia J. Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney Int 2002;61:1537-44.
97. Hagenfeldt Y, Linde K, Sjoberg HE, Zumkeller W, Arver S. Testosterone increases serum 1,25-dihydroxyvitamin D and insulin-like growth factor-I (IGF-1) in hypogonadal men. Int J Androl 1992;15:93-102.
98. Hobbs CJ, Plymate SR, Rosen CJ, Adler RA. Testosterone administration increases insulin-like growth factor-I levels in normal men. J Clin Endocrinol Metab 1993;77:776-9.
99. Ballal SH, Domoto DT, Polack DC, Mardciulonis P, Martin KJ. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 1991;17:29-33.
100. Gaughan WJ, Liss KA, Dunn SR, Mangold AM, Buhsmer JP, Michail B et al. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Am J Kidney Dis 1997;30:495-500.
101. Berns JS, Rudnick MR, Cohen RM. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clin Nephrol 1992;37:264-7.
102. Teruel JL, Marcen R, Navarro-Antolin J, Aguilera A, Fernandez-Juarez G, Ortuno J. Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: a prospective study. J Am Soc Nephrol 1996;7:140-4.
103. Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis. JAMA 1998;281:1275-81.
104. Johansen KL. The role of nandrolone decanoate in patients with end stage renal disease in the erythropoietin era. Int J Artif Organs 2001;24:183-5.
105. Teruel JL, Lasuncion MA, Rivera M, Aguilera A, Ortega H, Tato A et al. Nandrolone decanoate reduces serum lipoprotein (a) concentration in hemodialysis patients. Am J Kidney Dis 1997;29:569-75.